With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.89891-65-6,7-Bromo-2-chloroquinoxaline,as a common compound, the synthetic route is as follows.
89891-65-6, a) 7-bromoquinoxaline-2-amine 7-bromo-2-chloroquinoxaline (1.0 g, 4.13 mmol) and ammonia (7 mL) were added to 1,4-dioxane (7 mL). After reaction under agitation at 70 C for 5 h, the reaction mixture was cooled to rt. Water (10 mL) was added, and EA (30 mL*2) was used for extraction. The organic phases were combined, washed with a saturated saline solution (50 mL), dried with anhydrous sodium sulfate, filtered, and concentrated at reduced pressure to obtain a crude compound. Isolation and purification by column chromatography (silica gel, PE: EA = 3:1 as an eluant) were performed to obtain the targeted compound (500 mg, 54.2% yield, yellow solid). LC-MS (ESI): m/z (M+1) 223.99.
As the paragraph descriping shows that 89891-65-6 is playing an increasingly important role.
Reference£º
Patent; Impact Therapeutics, Inc; CAI, Suixiong; TIAN, Ye Edward; (74 pag.)EP3567041; (2019); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider